Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis
Written By
Meyers T, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Denson K, Hovind L, Sise T, Teppler H, Mathiba SR, Masenya M, Hesseling A, Cotton MF, Krogstad P, IMPAACT P1101 Team
